Ignite Creation Date:
2024-05-05 @ 5:01 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00376220
Status:
COMPLETED
Last Update Posted:
2017-04-11
First Post:
2006-09-13
Brief Title:
A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression
Sponsor:
Johns Hopkins University
Organization:
Johns Hopkins University
Study Overview
Official Title:
A Double-Blind Placebo Controlled Trial of Riluzole in Bipolar Depression
Status:
COMPLETED
Status Verified Date:
2017-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The Johns Hopkins Department of Psychiatry is conducting a research study to examine the effectiveness of riluzole in treating the depressed phase of bipolar disorder This outpatient treatment study of medication or placebo will last 9-12 weeks The study includes medical and psychiatric evaluations as well as time-limited medication treatment at no cost and you will be compensated for your participation
Detailed Description:
The study will last 8 to 12 weeks and requires weekly visits Participants will come to Johns Hopkins for a screening visit during which they will talk with a psychiatrist answer questions about their mood and symptoms have their blood drawn and have a brief physical exam If they meet criteria for the study any antidepressant medication that they are taking will be tapered and stopped before beginning study medications Participation in the study includes free study medication labs and testing plus reimbursement for transportation Participants will also be paid and after the study referred back to their treating psychiatrist with treatment recommendations
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None